Drug
HLX87 + Pertuzumab
HLX87 + Pertuzumab is a pharmaceutical drug with 2 clinical trials. Currently 1 active trials ongoing.
Total Trials
2
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
1(50%)
Phase Distribution
Ph phase_2
2
100%
Phase Distribution
0
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 2Efficacy & side effects
2(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
2
all time
Status Distribution
Active(2)
Detailed Status
Not yet recruiting1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
2
Active
1
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 22 (100.0%)
Trials by Status
not_yet_recruiting150%
recruiting150%
Recent Activity
1 active trials
Showing 2 of 2
recruitingphase_2
A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer
NCT07294508
not_yet_recruitingphase_2
A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer
NCT07294534
Clinical Trials (2)
Showing 2 of 2 trials
NCT07294508Phase 2
A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer
NCT07294534Phase 2
A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer
All 2 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 2